Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized open-label study of pucotenlimab plus TACE as first-line treatment for stage IV M1c melanoma with liver metastases
CTR20222648Phase 3Active
- Sponsor
- Lepu Biopharma Co., Ltd.
- Start
- Feb 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pucotenlimab in melanoma, sponsored by Lepu Biopharma Co., Ltd. Primary endpoints: Progression-free survival and Overall survival. Started Feb 2023; status: active.
02
Drugs
pucotenlimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20222648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222648.